Your browser doesn't support javascript.
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum.
Barnes, Geoffrey D; Burnett, Allison; Allen, Arthur; Ansell, Jack; Blumenstein, Marilyn; Clark, Nathan P; Crowther, Mark; Dager, William E; Deitelzweig, Steven B; Ellsworth, Stacy; Garcia, David; Kaatz, Scott; Raffini, Leslie; Rajasekhar, Anita; Beek, Andrea Van; Minichiello, Tracy.
  • Barnes GD; University of Michigan, 2800 Plymouth Rd, B14 G214, 48109-2800, Ann Arbor, MI, USA. gbarnes@med.umich.edu.
  • Burnett A; University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • Allen A; VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
  • Ansell J; Professor of Medicine, Hofstra/Northwell School of Medicine , New York, USA.
  • Blumenstein M; Children's Hospital of Philadelphia , Philadelphia, PA, USA.
  • Clark NP; Kaiser Permanente Colorado, Colorado University Skaggs School of Pharmacy, Aurora, CO, USA.
  • Crowther M; McMaster University, Hamilton, ON, Canada.
  • Dager WE; UC Davis Medical Center, Sacramento, CA, USA.
  • Deitelzweig SB; Ochsner Health System, New Orleans, LA, USA.
  • Ellsworth S; Henry Ford Hospital, Detroit, MI, USA.
  • Garcia D; University of Washington, Seattle, WA, USA.
  • Kaatz S; Henry Ford Hospital, Detroit, MI, USA.
  • Raffini L; University of Pennsylvania Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Rajasekhar A; University of Florida Health, Visalia, CA, USA.
  • Beek AV; Kaweah Health Medical Group/Visalia Medical Clinic, Visalia, CA, USA.
  • Minichiello T; University of California, San Francisco San Francisco VA Medical Center, San Francisco, CA, USA.
J Thromb Thrombolysis ; 54(2): 197-210, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1844435
ABSTRACT
Thromboembolism is a common and deadly consequence of COVID-19 infection for hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and early observational reports, expert consensus and guidance documents have strongly encouraged the use of prophylactic anticoagulation for patients hospitalized for COVID-19 infection. More recently, multiple clinical trials and larger observational studies have provided evidence for tailoring the approach to thromboprophylaxis for patients with COVID-19. This document provides updated guidance for the use of anticoagulant therapies in patients with COVID-19 from the Anticoagulation Forum, the leading North American organization of anticoagulation providers. We discuss ambulatory, in-hospital, and post-hospital thromboprophylaxis strategies as well as provide guidance for patients with thrombotic conditions who are considering COVID-19 vaccination.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Venous Thromboembolism / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Thromb Thrombolysis Journal subject: Vascular Diseases Year: 2022 Document Type: Article Affiliation country: S11239-022-02643-3

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Venous Thromboembolism / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Thromb Thrombolysis Journal subject: Vascular Diseases Year: 2022 Document Type: Article Affiliation country: S11239-022-02643-3